This grant supports early-stage clinical trials and related activities to develop innovative, safe, and effective therapeutic interventions for neurodegenerative diseases, excluding rare neurodegenerative diseases. The objective is to advance state-of-the-art knowledge, methodologies, and technologies to improve clinical practices and patient outcomes, foster collaboration among scientific and clinical communities, integrate and utilize data sharing infrastructures, and actively engage patients and caregivers. Proposals are expected to combine pharmacological interventions with multidisciplinary approaches, address clinical trial rigor, further understand mechanisms of action, utilize digital and AI technologies for monitoring and assessment, and promote inclusive, bias-free, and ethically sound methodologies. Participation of SMEs, incorporation of social sciences and humanities, and engagement with relevant stakeholders are encouraged.
| Agency | HORIZON (EU) |
|---|---|
| Region | EUUKUSAother |
| Country | N/A |
| Legal form | Company, NGO, Government organization, House union, Other |
| Start date | 10 Feb 2027 |
| End date | 13 Apr 2027 |
| Max funding | 10,000,000 EUR per grant |
| Budget | 39,300,000 EUR (2027 topic budget) |
| Coverage | Union funding is available to eligible entities from Member States, Associated Countries, and the USA; conditions for other non-EU/non-Associated Countries apply as per Horizon Europe work programme. Funding covers eligible project costs as per Horizon Europe rules. |